Stock A298380 ABL BIO INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings ABL Bio Inc.

Equities

A298380

KR7298380007

End-of-day quote Korea S.E.
Other stock markets
 23:00:00 19/05/2024 BST 		5-day change 1st Jan Change
25,550 KRW +1.39% Intraday chart for ABL Bio Inc. +8.49% +3.86%
03-25 Biocytogen Pharmaceuticals Co., Ltd. Enters Collaboration with ABL Bio Inc. to Develop New Bispecific Antibody-Drug Conjugates CI
2023 ABL Bio Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI

Weaknesses

  • According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • Low profitability weakens the company.
  • The company appears highly valued given the size of its balance sheet.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
ABL BIO INC. Stock ABL Bio Inc.
+3.86% 900M - -
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+9.58% 115B
B+
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+12.41% 107B
B+
ARGENX SE Stock argenx SE
-2.59% 21.6B
B
BIONTECH SE Stock BioNTech SE
-12.38% 22.31B
B+
GENMAB A/S Stock Genmab A/S
-5.29% 19.19B
A-
BEIGENE, LTD. Stock BeiGene, Ltd.
-3.35% 18.23B
B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-38.57% 17.62B
A-
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+7.51% 14.26B
C+
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+35.67% 12.37B
C+
Investor Rating
-
Trading Rating
-
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
-
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
-
4 months EPS revision

Consensus

Analyst Opinion
-
Potential Price Target
-
4m Target Price Revision
-
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
-

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. A298380 Stock
  4. Ratings ABL Bio Inc.